Research progress on 3β-hydroxysteroid dehydrogenase and metabolic diseases
包余婕 1丁波 1马建华1
扫码查看
点击上方二维码区域，可以放大扫码查看
作者信息
1. 南京医科大学附属南京医院（南京市第一医院） 内分泌代谢科，南京 210012
折叠
摘要
3β-羟基类固醇脱氢酶(3β-hydroxysteroid dehydrogenase，3β-HSD)参与多种甾体激素的合成，是影响代谢性疾病发生发展的重要生物标志物，以3β-HSD作为治疗靶点的药物已经成为了近年的研究热点。此文就3β-HSD在糖尿病、肥胖、高血压、多囊卵巢综合征以及非酒精性脂肪肝中潜在生理病理机制及临床应用前景的最新研究进展进行总结。 3β-hydroxysteroid dehydrogenase (3β-HSD) participates in the synthesis of a variety of steroid hormones and acts as an important biomarker that affects the occurrence and development of metabolic diseases. Drugs targeting 3β-HSD have become a research hotspot in recent years. In this paper, we summarize the latest research of the potential pathophysiological mechanism and clinical application prospect of 3β-HSD in diabetes, obesity, hypertension, polycystic ovary syndrome and nonalcoholic fatty liver disease.
Abstract
3β-hydroxysteroid dehydrogenase (3β-HSD) participates in the synthesis of a variety of steroid hormones and acts as an important biomarker that affects the occurrence and development of metabolic diseases. Drugs targeting 3β-HSD have become a research hotspot in recent years. In this paper, we summarize the latest research of the potential pathophysiological mechanism and clinical application prospect of 3β-HSD in diabetes, obesity, hypertension, polycystic ovary syndrome and nonalcoholic fatty liver disease.
万方数据